FREE Account Opening + No Clearing Fees
Loading...

Integra Essentia Rights Issue 2024 vs Solara Active Pharma Sciences Rights Issue 2024

Comparision between Integra Essentia Rights Issue 2024 and Solara Active Pharma Sciences Rights Issue 2024.

Rights Issue details

Find important information like Listing Exchange, Terms of payment and Entitlement Ratio for Integra Essentia Rights Issue 2024 and Solara Active Pharma Sciences Rights Issue 2024. Integra Essentia Rights Issue 2024 is listed on BSE, NSE while Solara Active Pharma Sciences Rights Issue 2024 is listed on BSE, NSE.

  Integra Essentia Limited Solara Active Pharma Sciences Ltd
Logo Integra Essentia Rights Issue 2024 Logo Solara Active Pharma Sciences Rights Issue 2024 Logo
Listing At BSE, NSE BSE, NSE
Terms of Payment

As per Terms of Payment : Issue Price - Fully payable on Application

Issue Price of Rs.375/- per share is payable as Rs.131.25 per share on Application. The remaining amount will be called within 24 months from the date of allotment in the Issue or within such extended period as may be determined by the Board or Rights Issue Committee of the Company at its sole discretion from time to time.

Entitlement 20 Rights Equity Share(s) for every 119 fully paid-up Equity Shares held on Record Date 1 Rights Equity Share(s) for every 3 fully paid-up Equity Shares held on Record Date
Application Form Application Form Application Form
Letter of Offer Letter of Offer Letter of Offer
Registrar Skyline Financial Services Private Ltd Cameo Corporate Services Limited
Lead Managers Fast Track Finsec Pvt Ltd Choice Capital Advisors Pvt Ltd

Rights Issue Size and Price

The issue size of Integra Essentia Rights Issue 2024 rights issue is ₹49.93 Crores, whereas Solara Active Pharma Sciences Rights Issue 2024 rights issue size is ₹449.95 Crores.

  Integra Essentia Limited Solara Active Pharma Sciences Ltd
Issue Size 15,36,24,538 shares 1,19,98,755 shares
Issue Size (Amount) ₹49.93 Crores ₹449.95 Crores
Issue Price ₹3.25 per share ₹375 per share
Face Value ₹1 per share ₹10 per share

Rights Issue Timetable

Find all the important dates related to the rights issue. The record date of Integra Essentia Rights Issue 2024 is Jun 01, 2024 while record date of Solara Active Pharma Sciences Rights Issue 2024 is May 15, 2024.

  Integra Essentia Limited Solara Active Pharma Sciences Ltd
Record Date Jun 01, 2024 May 15, 2024
Credit of Rights Entitlements May 27, 2024
Bid/Offer Opens On Jun 11, 2024 May 28, 2024
Renunciation of Rights Entitlements Jun 20, 2024 Jun 05, 2024
Bid/Offer Closes On Jun 25, 2024 Jun 11, 2024
Deemed Date of Allotment Jul 29, 2024 Jun 19, 2024
Credit Date Jul 02, 2024 Jun 19, 2024
Listing Date Jul 05, 2024 Jun 20, 2024

Financials details

Comparison of Integra Essentia Rights Issue 2024 and Solara Active Pharma Sciences Rights Issue 2024 financial data, including total revenue, PAT, and net worth. The table below also includes a list of all relevant documents like the Application Form and Letter of Offer. Related Parties like Lead Manager and Registrar are also mentioned in this section.

  Integra Essentia Limited Solara Active Pharma Sciences Ltd
Financial

Integra Essentia Limited Financial Information (Restated Consolidated)

Integra Essentia Limited's revenue increased by 257.83% and profit after tax (PAT) rose by 512.59% between the financial year ending with March 31, 2023 and March 31, 2022.

Period Ended31 Dec 202331 Mar 202331 Mar 202231 Mar 2021
Assets186.00160.9716.880.16
Revenue194.97245.5068.610.00
Profit After Tax9.496.671.09-0.61
Net Worth112.3375.41-29.11-30.20
Total Borrowing0.850.030.030.03
Amount in ₹ Crore

Solara Active Pharma Sciences Ltd Financial Information (Restated Consolidated)

Solara Active Pharma Sciences Ltd's revenue increased by 13.82% and profit after tax (PAT) rose by 61.85% between the financial year ending with March 31, 2023 and March 31, 2022.

Period Ended31 Mar 202331 Mar 202231 Mar 2021
Assets28.9929.4526.14
Revenue14.6612.8816.46
Profit After Tax-0.22-0.582.21
Amount in ₹ Crore

Comments

Add a public comment...